AtaiBeckleyNASDAQ: ATAI

AtaiBeckley is a clinical-stage biopharmaceutical company listed on NASDAQ (ATAI), formed in November 2025 through the strategic combination of atai Life Sciences and Beckley Psytech. Incorporated in Delaware with headquarters in New York, the company develops rapid-acting, durable psychedelic-based treatments for serious mental health conditions with significant unmet need. Its lead asset, BPL-003, is a proprietary intranasal formulation of 5-MeO-DMT (mebufotenin benzoate) that received FDA Breakthrough Therapy Designation for treatment-resistant depression and delivered compelling Phase 2b results. The merger was approved by approximately 98% of atai shareholders in an all-share transaction valued at around $390 million, creating a pipeline spanning three active Phase 2 programmes. AtaiBeckley holds a strong IP portfolio with granted US patents through 2043 and reported cash runway into 2029.